Skip to content

Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva

Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva (COVID-19)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04578509
Acronym
SALICOV
Enrollment
5197
Registered
2020-10-08
Start date
2020-10-19
Completion date
2021-06-09
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, SARS-CoV-2 Infection

Keywords

Screening program, SARS-CoV-2 infection

Brief summary

The investigators hypothesize that detection of SARS-CoV2 on saliva samples will increase the performance of the screening program compared to the reference strategy (RT-PCR on a nasopharyngeal swab).

Detailed description

Containment of the COVID19 pandemic relies on mass screening to allow rapid identification and isolation of cases to break transmission chains. The reference diagnostic method is based on detection of viral genomes by PCR on a nasopharyngeal swab sample (NPS). However, the pandemic has generated a very high demand causing a shortage of specific swabs and difficulties in the supply of reagents and consumables. Nasopharyngeal sampling requires skilled personnel, and is sometimes poorly accepted by patients. These issues can reduce the quality of sampling and therefore the sensitivity of the test. This strategy also requires sending samples to specialized laboratories, generating a delay in providing results. New diagnostic approaches on saliva samples are being developed allowing 1) an easier sampling procedure and 2) a diagnostic technique that can be performed in point-of-care. Previous evaluations suggest that these approaches have a lower sensitivity than the reference strategy (PCR on NPS), around 50 to 90% depending on the technique used. Despite lower sensitivity compared to the reference strategy, the investigators hypothesize that detection of SARS-CoV2 on saliva samples will improve the performance of the screening program by considerably increasing the number of individuals tested in shorter times. The main objective of the study is to evaluate, for the detection of SARS-CoV-2 infection, the performance of various alternative virological diagnostic strategies on saliva samples, in comparison with the reference technique (RT-PCR on NPS). The primary endpoint of the study is positivity of the standard technique (RT-PCR on NPS) for the SARS-CoV-2 virus. The result of the alternative strategies on a saliva sample will be considered as positive or negative according to criteria specific to each of them and compared to the result of the reference technique to estimate their respective sensitivity. The secondary objectives are to compare the diagnostic performances of RT-PCR on saliva versus RT-PCR on NPS, the diagnostic performances of alternative techniques on saliva versus RT-PCR on saliva, to evaluate the acceptability of the saliva self-sampling and the cost-effectiveness of new diagnostic strategies compared to the reference technique. The study will include adults and children in whom a NPS is performed for SARS-CoV-2 screening. After informed consent, participants will be asked to provide a saliva sample before nasopharyngeal sampling. Both samples will be analyzed in parallel. The analytical performance of each technique will be assessed, centrally or delocalised, depending on the feasibility of the techniques and according to the advice of the scientific board. The analyzes will be carried out by a team of technicians specifically recruited for the study. All samples collected will be stored in a centralized in a biobank.

Interventions

DIAGNOSTIC_TESTNasopharyngeal swab

Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test

DIAGNOSTIC_TESTSaliva sample

Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach

DIAGNOSTIC_TESTaxillary sweat sample

Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.

OTHERData collection

Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Adult or child subject able to receive nasopharyngeal swab, regardless of age * Subject in whom nasopharyngeal swab is performed for detection of SARS-CoV-2 as part of the screening system managed by APHP * Subject or parent not opposed to saliva sampling and data collection as part of this research

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Positivity of RT-PCR on nasopharyngeal swab for the SARS-CoV-2 virusAt diagnosisRT-PCR on nasopharyngeal is considered as gold standard

Secondary

MeasureTime frameDescription
Positivity of RT-PCR on saliva sample for the SARS-CoV-2 virusAt diagnosis
Positivity of new detection approach on saliva sample for the SARS-CoV-2 virusAt diagnosis
Positivity of antigenic test on nasopharyngeal swab for the SARS-CoV-2 virusAt diagnosis
Practicability to samplesAt diagnosisNumber of samples tested in a day for each test
Practicability to premisesAt diagnosisQuantity of premises required for each test
Practicability to interpretationAt diagnosisFeasibly Reading and interpretation For each test
Practicability to render timeAt diagnosisRender times for each test
IgG Antibody detection in salivaAt diagnosisResearch of IgG by ELISA and RDT
IgM Antibody detection in salivaAt diagnosisResearch of IgM by ELISA and RDT
IgA Antibody detection in salivaAt diagnosisResearch of IgA by ELISA and RDT
Positivity of canine olfactory detection of SARS-CoV-2At diagnosis
Patient tolerance of the salivary self-samplingAt diagnosisEvaluation by questionnaire of the patient tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions are about pain, discomfort, speed of performance)
Operator tolerance of the salivary self-samplingAt diagnosisEvaluation by questionnaire of the operator tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions is about pain, discomfort, speed of performance)
Cost of each approachAt diagnosisIncluding sampling, transport, technique (consumables, reagents, machine), human resources

Countries

France

Contacts

STUDY_DIRECTORJérôme Le Goff, Professor

Assistance Publique - Hôpitaux de Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026